Showing results (131-140 of 144) with videos related to

Sort By:
Pageof 15
Journal of Nanobiotechnology|May 5, 2021
Exploiting the anticancer effects of a nitrogen bisphosphonate nanomedicine for glioblastoma multiformeLynn N Jena, Lindsey A Bennie, Emma M McErlean, et al.
International Journal of Cancer|May 1, 2013
Cathepsin S from both tumor and tumor-associated cells promote cancer growth and neovascularizationDonna M Small, Roberta E Burden, Jakub Jaworski, et al.
Frontiers in Pharmacology|December 20, 2023
Evaluation of variable new antigen receptors (vNARs) as a novel cathepsin S (CTSS) targeting strategyP Smyth, L Ferguson, J F Burrows, et al.
Oncotarget|July 16, 2014
USP17 is required for clathrin mediated endocytosis of epidermal growth factor receptorJakub Jaworski, Michelle de la Vega, Sarah J Fletcher, et al.
Nature Communications|March 31, 2011
The deubiquitinating enzyme USP17 is essential for GTPase subcellular localization and cell motilityMichelle de la Vega, Alyson A Kelvin, Dara J Dunican, et al.
The Journal of Biological Chemistry|February 4, 2009
USP17 regulates Ras activation and cell proliferation by blocking RCE1 activityJames F Burrows, Alyson A Kelvin, Cheryl McFarlane, et al.
Journal of Immunology (Baltimore, Md. : 1950)|November 26, 2009
Siglec-E is up-regulated and phosphorylated following lipopolysaccharide stimulation in order to limit TLR-driven cytokine productionCaroline R Boyd, Selinda J Orr, Shaun Spence, et al.
The Medical Journal of Australia|October 6, 2001
Anticoagulation in pregnancy and the puerperiumW M Hague, R A North, A S Gallus, et al.
EMBO Reports|January 26, 2022
USP17 is required for peripheral trafficking of lysosomesJia Lin, Aidan P McCann, Naphannop Sereesongsaeng, et al.
Molecular Cancer Therapeutics|September 5, 2013
A highly potent and specific MET therapeutic protein antagonist with both ligand-dependent and ligand-independent activityShane A Olwill, Christian Joffroy, Hendrik Gille, et al.
Pageof 15